Arcturus Therapeutics partners with Thermo Fisher to support Phase 3 development of cystic fibrosis therapy ARCT-032

Thermo Fisher Scientific Inc.
Arcturus Therapeutics

Thermo Fisher Scientific Inc.

TMO

0.00

Arcturus Therapeutics

ARCT

0.00
  • Arcturus entered a strategic collaboration with Thermo Fisher to support Phase 3 development of ARCT-032, its investigational mRNA therapy for cystic fibrosis.
  • Thermo Fisher will provide integrated manufacturing, clinical research, commercial readiness services via its Accelerator Drug Development platform.
  • Thermo Fisher will supply Phase 3 manufacturing services; Arcturus expects to run Phase 3 through Thermo Fisher’s PPD clinical research unit if Phase 2 is positive.
  • Subject to regulatory approval, Thermo Fisher will receive exclusive commercial manufacturing rights under a separate commercial agreement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607020700BIZWIRE_USPR_____20260702_BW861323) on July 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.